{
    "id": 27093,
    "cites": 38,
    "cited_by": 1,
    "reference": [
        "Acemolgu, D. and J. Linn, (2004), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 119(3): 1049-1090.",
        "Angell, M., (2010), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Bad Pharma, Bad Medicine,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Boston Review, accessed at: http://bostonreview.net/angell-big-pharma-bad-medicine Arcidiacono, P., Ellickson, P., Landry, P., and Ridley, D. B. (2013), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical Followers,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of Industrial Organization, 31(5), 538-553.",
        "Bast, J. (2004), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Pros and Cons of Importing Drugs from Canada\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Press Release by the Heartland Institute, 4/19/2014.",
        "Boyd, D. B. (1999). Is rational design good for anything? ACS Publications Branstetter, L., Chatterjee, C., and M. Higgins (2016) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regulation and Welfare: Evidence from paragraph IV Generic Entry in the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The RAND Journal of Economics, 47(4), 857-890.",
        "Blume-Kohout, M. and N. Sood (2013) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics, 97: 327\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c336.",
        "Cerda, R. (2007), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Endogenous Innovations in the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Evolutionary Economics, 17 (4): 473\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c515.",
        "Chandra, A., Garthwaite, G., Stern, A, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Characterizing the Drug Development Pipeline for Precision Medicine,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Economic Dimensions of Personalized and Precision Medicine, 2019, National Bureau of Economic Research, Inc.",
        "Chaudhuri, S., Goldberg, P., and P. Jia (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 96(5), 1477-1514.",
        "Doshi, P., Dickersin, K., Healy, D., Vedula, S. S., & Jefferson, T. (2013). Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ, 346, f2865.",
        "Dranove, David, Craig Garthwaite, and Manuel Hermosilla (2014). Pharmaceutical profits and the social value of innovation. National Bureau of Economic Research Working Paper No. 20212.",
        "Drews, J. (2003). Strategic trends in the drug industry. Drug discovery today, 8(9), 411-420.",
        "Dutta, A. (2011), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093From Free Entry to Patent Protection: Welfare Implications for the Indian Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Review of Economics and Statistics, 93(1), 160-178.",
        "Ernst & Young (2012), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Beyond Borders: Global Biotechnology Report\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Finkelstein, A. (2004), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 119(2): 527-564 Fishman, M. C., & Porter, J. A. (2005). A new grammar for drug discovery. Nature, 437(7058), 491.",
        "Gaessler, F., & Wagner, S. (2019). Patents, data exclusivity, and the development of new drugs. Available at SSRN 3401226.",
        "Granlund, D. (2010), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Price and Welfare Effects of a Pharmaceutical Substitution Reform,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 29(6), 856-865.",
        "Engelhardt, G. V., & Gruber, J. (2011). Medicare Part D and the financial protection of the elderly. American Economic Journal: Economic Policy, 3(4), 77-102.",
        "Hall, B. H., Jaffe, A., & Trajtenberg, M. (2005). Market value and patent citations. RAND Journal of Economics, 16-38.",
        "Hara, T. (2003). Innovation in the pharmaceutical industry: the process of drug discovery and development. Edward Elgar Publishing.",
        "Hermosilla, M. (2019). Rushed Innovation: Evidence from drug Licensing. Forthcoming in Management Science.",
        "Johnson, M. A. and G. M. Maggiora (1990). Concepts and applications of molecular similarity. Wiley Kesselheim, A. S., Wang, B., & Avorn, J. (2013). Defining \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093innovativeness\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in drug development: a systematic review. Clinical Pharmacology & Therapeutics, 94(3), 336-348.",
        "Ketcham, J. and K. Simon (2008), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicare Part D\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s effects on Elderly drug costs and utilization\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Journal of Managed Care, 14(11): 14-22.",
        "Kneller, R. (2010). The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Reviews Drug Discovery, 9(11), 867.",
        "Krieger, J. L., Li, D., & Papanikolaou, D. (2018). Developing novel drugs (No. w24595). National Bureau of Economic Research.",
        "Krieger, J.L. (2019). Trials and Terminations: Learning from Competitors\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 R&D Failure. Working Paper Harvard Business School.",
        "Kyle, M. and A. McGahan (2012), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Investments in Pharmaceuticals Before and After TRIPS\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economics and Statistics, 94(4): 1157-1172.",
        "Lanthier, M., Miller, K. L., Nardinelli, C., & Woodcock, J. (2013). An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2011. Health Affairs, 32(8), 1433-1439.",
        "Liu, Angus, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Gilead\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s stealing hep C share with its cut-rate Eplusa and Harvoni generics,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d FiercePharma, Sep 26, 2019. Accessed at: https://www.fiercepharma.com/pharma/gilead-s-authorized-hcvgenerics -now-own-over-20-market on 3/21/2020.",
        "Lowe, Derek (November 4, 2010), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Where Drugs Come From: The Numbers\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Blog post for \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093In the Pipeline\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d https://blogs.sciencemag.org/pipeline/archives/2010/11/04/where_drugs_come_from_the_numb ers Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature reviews Drug discovery, 3(4), 353.",
        "Sams-Dodd, F. (2005). Target-based drug discovery: is something wrong?. Drug discovery today, 10(2), 139-147.",
        "Swinney, David C., and Jason Anthony. How were new medicines discovered? Nature reviews Drug discovery 10.7 (2011): 507.",
        "Swinney, D. C. (2004). Biochemical mechanisms of drug action: what does it take for success? Nature reviews Drug discovery, 3(9), 801.",
        "Tobert, J. A. (2003). Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature reviews Drug discovery, 2(7), 517.",
        "Trajtenberg, M. (1990). A penny for your quotes: patent citations and the value of innovations. RAND Journal of Economics, 172-187.",
        "Shih, H. P., Zhang, X., & Aronov, A. M. (2018). Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nature Reviews Drug Discovery, 17(1), 19.",
        "Ward, M. and D. Dranove (1997), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Vertical Chain of Research and Development in the Pharmaceutical Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Economic Inquiry, 33(1): 70-87.",
        "Yin, W., Basu, A., Zhang, J., Rabbani, A., Meltzer, D., and C. Alexander (2008), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Annals of Internal Medicine, 148(3): 169-177.",
        "Zheng, C. J., Han, L. Y., Yap, C. W., Xie, B., & Chen, Y. Z. (2006). Progress and problems in the exploration of therapeutic targets (vol 11, pg 412, 2006). Drug Discovery Today, 11(15-16), 717-717.",
        "Zimmermann, G. R., Lehar, J., & Keith, C. T. (2007). Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug discovery today, 12(1-2), 34-42."
    ]
}